Current Report · Items 2.02, 9.01 · 8-K

Kura Oncology, Inc.

KURANASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed May 12, 2026Accepted May 12, 2026, 4:10 PM EDTCIK 1422143Accession 0001193125-26-219422

Company context

Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.

Current securities

KURANASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On May 12, 2026, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2026 and providing a corporate update. A copy of this press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

Filed exhibits (1)

EX-99.1 (by filename) kura-ex99_1.htm

EX-99.1 2 kura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kura Oncology Reports FIRST Quarter 2026 Financial Results - $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization - - Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum - - Broad and rapid payer access achieved, with > 93% coverage and favorable positioning across > 12 million lives - - Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML - - $580.8 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program through first topline KOMET-017 Phase 3 results - - Management to host webcast and conference call today at 4:30 p.m. ET - SAN DIEGO, May 12, 2026 - Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for cancer, today reported first quarter 2026 financial results and provided a corporate update. “In its first full quarter of commercial availability, KOMZIFTI generate…

Open exhibit ↗

Free Registration